It is a promising therapeutic agent for solid organ transplantations and cancer treatments.4 In addition to the direct antiproliferative effect on tumour cells, rapamycin impedes tumour growth by blocking angiogenesis in a mouse metastatic cancer model.5 LBH589 (panobinostat), a non‐selective histone deacetylase inhibitor (pan‐HDAC inhibitor), has been shown to induce tumour shrinkage and sustain stable disease status in a phase II trial of pre‐treated lung cancer patients.6 LBH589 is the first HDAC inhibitor to be approved by the FDA to treat multiple myeloma patients.7 This evidence concerns the gene HDAC9 and neoplasm.